SOURCE: World Street Fundamentals

May 18, 2011 09:00 ET

Biotech Approaching Inflection Point - Equity Research on Marina Biotech, Inc. and Arrowhead Research Corporation

HONG KONG--(Marketwire - May 18, 2011) - Today, www.WorldStreetFundamentals.com released its industry report highlighting Marina Biotech, Inc. (NASDAQ: MRNA) and Arrowhead Research Corporation (NASDAQ: ARWR). Full fundamental and technical analysis is available at www.WorldStreetFundamentals.com/Reports.php.

Biotech is enabling creation of new drugs at a faster pace than the traditional pharmaceutical model and some believe that after a decade of mediocre performance it is approaching an inflection point. Companies are much more conducive to focusing on productivity and the sector is showing signs of being back to top growth by 2013 due to the opportunity emerging markets have created.

World Street Fundamentals has highlighted Marina Biotech because for its focus on the discovery, development and commercialization of pharmaceuticals based on RNA interference (RNAi). Its infrastructure provides for pre-clinical scale manufacturing of both siRNAs and delivery materials, the analysis and optimization of these compounds both individually and as drug candidates, and the filing of Investigational New Drug Applications. The Company develops RNAi-based product candidates for the treatment of cancer, metabolic disorders, inflammation, and viral infections. It focuses on siRNA constructs, such as dicer substrates and three-stranded meroduplexes, and delivery systems for improved siRNA delivery. MDRNA's various development programs consist of oncology; metabolic disorders, and inflammation. The entire report on Marina Biotech, Inc. (NASDAQ: MRNA) is available here: www.WorldStreetFundamentals.com/ViewFullReport.245.php.

World Street has highlighted Arrowhead Research Corporation for its position as a nanomedicine company engaged in development therapeutic products at the interface of biology and nano-engineering to cure disease and improve human health. Arrowhead is focused on the preclinical and clinical development of therapeutics for the treatment of cancer and obesity, as well as the regeneration of wounded or diseased tissue. Arrowhead's portfolio includes Calando Pharmaceuticals, Inc. (Calando), delivers small ribonucleic acid (RNA) for gene silencing; and Ablaris Therapeutics, Inc. (Ablaris), an anti-obesity therapeutics company; Nanotope, Inc. (Nanotope), a regenerative medicine company and Leonardo (Leonardo), a multi-stage drug delivery company. The entire report on Arrowhead Research Corporation (NASDAQ: ARWR) is available here: www.WorldStreetFundamentals.com/ViewFullReport.138.php.

About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets. Covering the top performers in the hottest sectors and providing clarity to investors around the world.

Contact Information